A recent dual‑target therapy that pairs a DGAT2 inhibitor with an ACC inhibitor has delivered remarkable results, helping 63‑66% of patients with metabolic dysfunction‑related steatohepatitis (MASH) achieve disease resolution—far better than placebo. Researchers also put two popular non‑invasive tools head‑to‑head, finding the MASH Resolution Index (MRI) outperforms the FAST score in predicting true disease reversal. In a novel twist, scientists at Renji Hospital discovered that remote limb ischemic preconditioning can boost liver fat metabolism. The benefit travels via tiny muscle‑derived extracellular vesicles carrying microRNA‑181d‑5p, opening a fresh therapeutic avenue. Semaglutide, the celebrated "weight‑loss wonder drug," was shown to reverse fatty‑liver damage by modulating 72 key proteins that control inflammation and fibrosis, highlighting its systemic metabolic power. A separate study unveiled a new TM7SF3‑hnRNPU‑TEAD1 signaling cascade that drives hepatic stellate cell activation and fibrosis, suggesting antisense oligonucleotide therapy could halt scar formation. Global health experts warn that MASLD/MASH is a mounting public‑health crisis, urging a three‑tiered prevention strategy and precision diagnostics. Phase‑2 data on efruxifermin revealed modest fibrosis gains at 36 weeks but a clear trend toward improvement by week 96, alongside better liver injury markers. Finally, Madrigal’s drug Resmetirom received FDA approval, marking the first official medication for MASH and offering new hope for millions worldwide.
Read moreTwo landmark Phase 3 trials led by Professor Zhou Caicun at Tongji University’s East Hospital have just reshaped the frontline fight against non‑small cell lung cancer (NSCLC). In the OptiTROP‑Lung05 study, a novel TROP2‑targeting antibody‑drug conjugate (sac‑TMT) was paired with the PD‑1 inhibitor pembrolizumab. The combination produced a 70.2% objective response rate versus 42.0% with pembrolizumab alone, and median progression‑free survival (PFS) has not yet been reached compared with just 5.7 months for the control group—a 65% cut in the risk of disease progression or death. This is the first global Phase 3 trial showing an ADC plus immunotherapy outperforms immunotherapy alone for PD‑L1‑positive, driver‑gene‑negative NSCLC. The second trial, WU‑KONG28, evaluated sunvozertinib, an oral, highly selective EGFR‑TKI designed for the notoriously hard‑to‑treat EGFR exon 20 insertion mutation. Sunvozertinib achieved a 58.9% response rate versus 31.1% for standard platinum‑based chemotherapy, extended PFS to 10.3 months (vs 7.5 months), and lowered the risk of progression or death by 35%. Both studies were presented at the ASCO meeting and published in the New England Journal of Medicine and The Lancet, highlighting China’s growing role in global oncology research. Professor Zhou also made history as the first Chinese chair of the International Association for the Study of Lung Cancer, underscoring the international impact of these breakthroughs.
Read moreA cutting‑edge medical‑technology hub called the A3 International Medical Technology Innovation Exchange Center has opened in Shanghai’s Oriental Hub Business Cooperation Zone. Led by Boston Scientific and built together with Danaher and Siemens Healthineers, the A3 Center is not a conventional exhibition hall – it’s an open ecosystem that links global innovators, Chinese hospitals and manufacturers. In the past five years China’s home‑grown medical‑device sector has leapt from copying foreign products to pioneering its own breakthroughs. Yet many of these inventions still stumble on the road to commercial scale because the local R&D system lacks some of the standards and production capacity of the world’s most advanced players. That’s where multinational partners step in, offering deep experience in research, manufacturing and regulatory navigation. Shanghai’s Cooperation Zone makes the whole process faster: visa‑free stays for foreign experts, tax incentives, streamlined approvals and a dense network of top‑tier hospitals and research labs. The city’s “Shanghai speed” turned the A3 concept into a reality in just a few months, giving innovators rapid access to clinical data, physician training and multi‑center trials. The A3 Center’s three pillars – Advanced technology, real‑world Application and AI‑driven insights – aim to turn daring lab discoveries into market‑ready solutions, shortening the gap between clinical problems and innovative answers. As Zhang Jun of Boston Scientific puts it, China is moving from a “large but not strong” market to a true leader in medical‑device innovation.
Read more